Three antigen candidates meet the criteria for CAR-T therapy for PCa and are currently under investigation: the epithelial cell adhesion molecule, prostate stem cell antigen and PSMA (reviewed by Perera et al. [149]). Here, FOLH1 is linked to posterior cortical atrophy.